DalsnaFinance

Nurix Therapeutics Inc $NRIX

Health Care

Russell 2000 California
Create a scorecard
$26.10
+1.17 (+4.69%)
As of Oct 20, 2026, 11:37 PM EDT
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Jul 27, 2026, the first target we tracked for NRIX.

Nurix Therapeutics Inc (NRIX) is trading up at $26.10 (+4.69%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

IPO: July 24, 2020 · $19.00 offering · NASDAQ · View IPO details →

Analyst price targets on NRIX

One firm's current price target on Nurix Therapeutics Inc: $38 — 46% above the current $26.1. Each is tracked to its date and scored the same way a member's call is.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Nurix Therapeutics Inc revenue & net income history (FY2019–FY2025)

RevenueNet incomeNet margin (right axis, %)
$84.0M−$90.2M−$264.5MFY2019 revenue: $31.1MFY2019 net income: −$21.7M · Net margin −69.7%'19FY2020 revenue: $17.8MFY2020 net income: −$43.2M · Net margin −242.7%'20FY2021 revenue: $29.8MFY2021 net income: −$117.2M · Net margin −393.9%'21FY2022 revenue: $38.6MFY2022 net income: −$180.4M · Net margin −466.9%'22FY2023 revenue: $77.0MFY2023 net income: −$143.9M · Net margin −187.0%'23FY2024 revenue: $54.5MFY2024 net income: −$193.6M · Net margin −354.9%'24FY2025 revenue: $84.0MFY2025 net income: −$264.5M · Net margin −314.9%'25−100%−50%0%FY2019 net margin: −69.7%FY2020 net margin: −242.7% (off the scale, which stops at −100.0%)FY2021 net margin: −393.9% (off the scale, which stops at −100.0%)FY2022 net margin: −466.9% (off the scale, which stops at −100.0%)FY2023 net margin: −187.0% (off the scale, which stops at −100.0%)FY2024 net margin: −354.9% (off the scale, which stops at −100.0%)FY2025 net margin: −314.9% (off the scale, which stops at −100.0%)
Nurix Therapeutics Inc annual financial statements
FY2019Nov 2019FY2020Nov 2020FY2021Nov 2021FY2022Nov 2022FY2023Nov 2023FY2024Nov 2024FY2025Nov 2025
Income statement
Revenue$31.1M$17.8M$29.8M$38.6M$77.0M$54.5M$84.0M
Growth (year over year)—−42.7%+66.9%+29.8%+99.3%−29.1%+54.0%
Operating income−$22.2M−$65.0M−$117.9M−$183.9M−$155.1M−$213.0M−$285.7M
Operating margin−71.5%−364.7%−396.3%−476.0%−201.4%−390.5%−340.2%
Net income−$21.7M−$43.2M−$117.2M−$180.4M−$143.9M−$193.6M−$264.5M
Net margin−69.7%−242.7%−393.9%−466.9%−187.0%−354.9%−314.9%
EPS (diluted)−$6.59−$2.76−$2.73−$3.71−$2.65−$2.88−$3.05
Balance sheet
Cash and equivalents$34.8M$119.4M$80.5M$64.5M$54.6M$110.0M$247.0M
Total assets$44.0M$396.3M$476.8M$416.8M$355.6M$669.3M$688.1M
Total liabilities$53.6M$106.1M$134.5M$113.1M$155.1M$142.3M$149.4M
Shareholders' equity−$57.7M$290.3M$342.3M$303.7M$200.5M$527.0M$538.7M
Cash flow
Operating cash flow$601.0K−$80.0K−$84.4M−$159.8M−$81.4M−$172.6M−$249.5M
Capital expenditure$1.65M$4.55M$5.66M$12.2M$8.40M$9.27M$14.0M
Free cash flow−$1.05M−$4.63M−$90.0M−$172.1M−$89.8M−$181.9M−$263.5M

From Nurix Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in November. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Nurix Therapeutics Inc

Headquarters
Brisbane, California From SEC filings, Oct 2026

Recent News (6)

More Health Care stocks

Browse all companies →